About
Company Profile
Company Introduction
R&D
Core Technology
PTS: Functional Mechanism
R&D Center
Paper Publish
History
Our Team
Partnership
Partnerships – Human Indication
Partnerships – Animal Drugs
News
Coming event
News Focus
Activites section
Announcement
Products
Para-Toluenesulfonamide (PTS)
PTS: Functional Mechanism
Product Features
Comparison with existing cancer treatments
Market Position
R&D
PTS100
PTS500
PTS02
GWA103
GWA106
Clinical Trials
Product progress
Compassionate use
Compassionate use cases
Partnership
Partnerships – Human Indication
Partnerships – Animal Drugs
Animals
Medical
Cosmetics
MAGIC SKIN GEL
DM
ROAN
DM
Pet Gel-Speedling
Investors
Important news
2026/9/24 To announce in accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
2026/9/19 On behalf of Tianjin Chase Sun Jiandakang, PTS Phase II HCC trial abstract in China accepted for presentation at ESMO Asia 2026.
2026/9/10 On behalf of subsidiary Tianjin Chase Sun Jiandakang, PTS-302 NDA was accepted for review in Morocco.
2026/09/05 Gongwin Pet Biopharm: Pet anti-cancer drug Gwa103 passes MOA technical review for NDA.
2026/8/25 In accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
2026/8/25 Company's Board of Directors has approved the consolidated financial report for the Second quarter of year 2026
Financial area
Annual Report
Monthly Revenue
2026
2025
2024
Consolidated Financial Reports
Shareholders area
Corporate Governance
Contact
下載產品DM
LINKEDIN
YOUTUBE
GO
中文
EN
INQUIRY
(
)
中文
EN
下載產品DM
SCROLL DOWN
Home
Animals
Canine-Products
Canine-Products
GWA103
Partner Hospitals
Journal publication
Health Education Materials
TOP
